5
May
2020

Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Mood Disorder R&D, Lacking Innovation, Turns to Psychedelics
Antibiotic Resistance Looms Large in Pandemic; CRISPR Phages Show Promise
Race and Life Sciences: Where is the Healing?
When Raising Drug Prices Helps Patients